Abstract

Bronchiolitis, characterized by inflammation of the bronchioles, presents significant health risks, particularly to infants, the elderly, and those with preexisting respiratory conditions. Traditionally associated with viral infections, bronchiolitis has recently been linked to electronic cigarette (e-cigarette) use, a trend that has surged in popularity over the past decade. While e-cigarettes are often marketed as safer alternatives to traditional smoking and are seen as viable tools for smoking cessation, emerging evidence suggests they may contribute to the onset or exacerbation of bronchiolitis and other respiratory conditions.
To address these concerns, we recommend a prescription model for e-cigarettes, particularly in the context of smoking cessation. This model would involve prescribing the minimum effective dose of e-liquid, tailored to individual factors such as age, gender, and health status, to reduce the risk of adverse effects. Additionally, developing a screening tool to assess the risk of e-cigarette or vaping-associated lung injury (EVALI) is crucial before recommending e-cigarettes as a cessation aid. Furthermore, we propose the implementation of a physical alert system, similar to those used for steroid or anticoagulant medications, to track the specific substances in e-liquids. This would aid clinicians in swift diagnosis and management. As the e-cigarette market continues to grow, careful regulation and further research are essential to prevent the public health consequences seen in the tobacco industry.